In this segment from Tuesday's Investor Beat, Motley Fool analyst Morgan Housel discusses the iShares NASDAQ Biotechnology Index (IBB 1.98%), and why he sees many tell-tale red flags that the biotech space is in a bubble right now. Morgan gives his insight on what these warning signs are, and whether or not the bubble could be near collapse.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.